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A B S T R A C T
An omnibus survey of microbiologists (n = 400)
and a survey of participants (n = 49) in the
Meropenem Yearly Susceptibility Test Informa-
tion Collection (MYSTIC) programme were
conducted to determine the awareness and
prevalence of extended-spectrum b-lactamases
(ESBLs), and the regularity and method of screen-
ing. Of the omnibus survey participants, 69%
screened regularly for ESBLs, compared with
83% of MYSTIC participants. In both surveys,
ESBLs were more common in Klebsiella pneumoni-
ae (73% and 79%, respectively) and Escherichia coli
(63% and 81%, respectively) than in other bac-
teria. The surveys demonstrated that awareness
of, and testing for, ESBLs is inconsistent.
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In order to make informed prescribing decisions,
clinicians need accurate information on the likely
antibiotic resistance profile of the organism caus-
ing the infection. Surveillance studies, such as the
Alexander Project, SENTRY and the Meropenem
Yearly Susceptibility Test Information Collection
(MYSTIC) programme, have been useful in pro-
viding accurate prevalence rates of specific bac-
terial resistance caused by different mechanisms,
such as extended-spectrum b-lactamases (ESBLs)
[1–3]. Infections caused by ESBL-producing path-
ogens may be associated with increases in mor-
tality, duration of hospital stay and hospital costs
[4,5]. However, awareness of the clinical import-
ance of ESBL-producing strains may vary consid-
erably among clinicians and microbiologists, with
continued surveillance and testing not performed
widely, and especially when the prevalence of
resistance is low. Therefore, two global surveys,
an omnibus survey and a survey of participants in
the MYSTIC programme, were conducted to
determine the degree of awareness of ESBLs, the
methods and frequency of ESBL screening, and
the reasons for not screening.
The omnibus survey comprised a panel of
microbiologists who participate regularly in tele-
phone interviews conducted by ISIS Research
(Putney, London, UK), an independent market
research agency. The respondents were not given
advance notice of the questions, and so were
asked to give an estimate when asked for
percentages. All participants in the MYSTIC
programme were sent a questionnaire. The two
surveys were performed during February and
March 2002. Both surveys included similar ques-
tions relating to perception of the incidence of
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ESBL-producing isolates, screening practices, and
the detection methods used (Table 1).
In total, 400 participants from 11 countries
worldwide participated in the omnibus telephone
survey. The self-completed questionnaire was
returned by 49 participants (of 81 participants
contacted) from 25 countries worldwide in the
MYSTIC programme.
In the omnibus survey, respondents were based
in a laboratory belonging to a non-specialist unit
(55%), an independent laboratory unattached to a
hospital (23%), a hospital (11%), or universities
and external laboratories (11%). Of all respond-
ents, 49% had taken part previously in antibiotic
resistance surveillance programmes.
Respondents from the MYSTIC programme
analysed samples from intensive care units
(25%), neutropenia units (13%), independent units
(11%), non-specialist units (8%) and cystic fibrosis
centres (6%). The remaining participants (37%)
worked in universities or external laboratories.
Of the omnibus survey participants, 69%
screened regularly for ESBLs, and 82% of these
had screened for ESBLs within the past month. Of
the participants who had screened for ESBLs
within the past month, 64% were participating in
surveillance studies. Of the 31% of respondents in
the omnibus survey who did not screen regularly
for ESBLs, most (73%) were not participating in
surveillance studies. Many (41%) of the microbi-
ologists in the omnibus survey who did not
screen regularly for ESBLs felt that it was unnec-
essary. Other reasons for not screening regularly
were a lack of facilities or funds (26%), or that
screening was dealt with by others (12%). A large
proportion (83%) of the MYSTIC participants
screened regularly for ESBLs, and 62% of these
had screened within the past month. In both
surveys, most participants who screened for
ESBLs did not identify them (51% and 67%, in
the omnibus and MYSTIC surveys, respectively).
The test usedmost commonly to detect ESBLs in
both surveys was the double-disk synergy test [6],
used by 47% and 57% of respondents in the
omnibus and MYSTIC surveys, respectively.
However, the Etest ESBL screen (AB Biodisk,
Solna, Sweden) was thought to be the most effica-
cious method by 27% and 40% of participants in
the omnibus and MYSTIC surveys, respectively.
In the past 12 months, most participants in both
surveys reported finding ESBLs in Klebsiella pneu-
moniae (73% and 79% of participants, respectively)
and Escherichia coli (63% and 81% of participants,
respectively) more often than in other bacteria
(Fig. 1). The overall prevalence, as estimated by
participants in the omnibus survey, of ESBL-
producing Enterobacter cloacae was 17%, with
13% of K. pneumoniae and 9% of E. coli isolates
also thought to be ESBL producers. Most partici-
pants in both surveys were very, or extremely,
concerned about the incidence of ESBL-producing
bacteria (52% in the omnibus survey, 66% in the
MYSTIC programme). The remainder were only
marginally or not at all concerned.
The results of the two surveys demonstrated
that, despite the high prevalence of ESBLs world-
wide, a considerable sub-section of the participants
Table 1. Overview of the two surveys on awareness and
perceptions of extended-spectrum b-lactamases (ESBLs)
Subject
Demographics
What type of ward or unit does your laboratory belong to?
Do you belong to an antibiotic resistance surveillance survey. If so, which one?
Frequency of screening for ESBLs
When did you last screen for ESBLs?
If you do not regularly screen for ESBLs, why not?
Prevalence of ESBL-producing isolates
During the past 12 months, specifically for your laboratory, in which of the
following bacteriaa have you found ESBLs?
In each of the bacteria you have listed, approximately what percentage of isolates
produce ESBLs?
Prevalence of ESBL types
In your experience, during the past 12 months, which ESBL types predominate?
Methods for detecting ESBLs
In general, which method do you employ to detect ESBLs?
In your view, which method is most efficacious?
Methods for typing ESBLs
In general, which method do you employ to type ESBLs?
In your view, which method is most efficacious?
aKlebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Proteus mirabilis, Morganella
morganii, Enterobacter cloacae, Enterobacter aerogenes, Pseudomonas aeruginosa, Acine-
tobacter baumannii, Acinetobacter anitratus, Acinetobacter lwoffii, Acinetobacter calco-
aceticus, Serratia marcescens, Citrobacter spp.
Fig. 1. Participants in the omnibus and MYSTIC surveys
reporting ESBL production among key pathogens within
the previous 12 months
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did not screen for these enzymes. Respondents
from the MYSTIC survey were more likely to
screen for ESBLs, and were more concerned about
the incidence of ESBL-producing bacteria than
respondents from the omnibus survey. This is not
surprising, as participants in surveillance studies
may be more aware of the issue of antimicrobial
resistance, which may be their initial reason for
enrolling in a surveillance study.
In both surveys, many participants who
screened for ESBLs did not identify them further,
either because it was thought unnecessary, or
because of lack of funding or facilities. Identifica-
tion of the particular type of ESBL that a resistant
organism produces will reveal the antibiotic
resistance profile of the organism and may help
clinicians to choose the most appropriate therapy
[7]. Where high prevalences of ESBL producers
are demonstrated as a result of surveillance
studies or screening, an appropriate initial empir-
ical therapy that covers ESBL-producing strains
should be considered. The double-disk synergy
test was the most common test used to detect
ESBLs in both surveys, but the Etest ESBL screen
was thought to be the most efficacious method.
The most appropriate screening methodology
should therefore be determined locally, according
to local resources.
Overall, the surveys demonstrated that aware-
ness of, and testing for, ESBLs is inconsistent.
Since ESBLs have an influence on morbidity and
mortality, and are associated with clinical failure,
it is important to increase the level of awareness
and frequency of testing for ESBLs.
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A B S T R A C T
Two oxacillin disk methods were compared with
a cefoxitin disk diffusion test for detection of
methicillin-resistant Staphylococcus aureus (MRSA),
with PCR for mecA as the reference method. When
tested with 115 MRSA and 350 methicillin-sus-
ceptible S. aureus isolates, the cefoxitin disk test
(specificity 100%, sensitivity 96.5%) was superior
to the oxacillin disk methods (specificity 99.1%,
sensitivity 90.4%). Testing with both oxacillin and
cefoxitin disks would give better sensitivity
(100%) than the cefoxitin test alone, but at the
expense of specificity (99.1%). The cefoxitin disk
test required no special test conditions and would
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